Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2049837 | 1.00 | SLC5A2 (0.81) | SLC5A2SLC5A1 | |
| SCHEMBL3892693 | 0.92 | SLC5A2 (0.81) | SLC5A2SLC5A1 | |
| SCHEMBL12757465 | 0.90 | SLC5A2 (0.84) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL18307653 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL18629778 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL2378682 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL3730054 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL17034639 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL17127189 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL16155105 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | claimed |
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | AJINOMOTO CO., INC. (JP) | 2007-03-29 | — | — | US | claimed |
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20100317575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO., INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO., INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-7645787-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-7645787-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070270479-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO. INC (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270479-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO. INC (JP) | 2007-11-22 | — | — | US | disclosed |
| US-7256209-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2007-08-14 | — | — | US | disclosed |
| US-7256209-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2007-08-14 | — | — | US | disclosed |
| US-7247616-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-7247616-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20070099979-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO. INC (JP) | 2007-05-03 | — | — | US | disclosed |
| US-20070099979-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO. INC (JP) | 2007-05-03 | — | — | US | disclosed |
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | AJINOMOTO CO., INC. (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270479-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | DPP4, SLC5A2, SLC5A1 | SLC5A2 2/4885SLC5A1 3/4885 |
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | IAPP, G6PC1, GPR119 | SLC5A2 6/4885SLC5A1 4/4885 |
| US-20070099979-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | DPP4, SLC5A2, SLC5A1 | SLC5A2 2/4885SLC5A1 3/4885 |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | DPP4, SLC5A2, SLC5A1 | SLC5A2 2/4885SLC5A1 3/4885 |
| US-20100317575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | SLC5A1, SLC5A2, G6PC1 | SLC5A2 2/4885SLC5A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.